vs
CNA FINANCIAL CORP（CNA）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
CNA FINANCIAL CORP的季度营收约是Ultragenyx Pharmaceutical Inc.的1.9倍（$389.0M vs $207.3M），CNA FINANCIAL CORP净利率更高（77.6% vs -62.0%，领先139.7%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs -2.0%），CNA FINANCIAL CORP自由现金流更多（$542.0M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs -2.2%）
CNA金融公司是总部位于美国伊利诺伊州芝加哥的金融企业，旗下核心子公司大陆意外伤害保险公司成立于1897年，大陆保险公司的历史则可追溯至1853年，当前母公司CNA于1967年正式注册成立，在保险及金融服务领域拥有深厚的行业积淀。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
CNA vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $389.0M | $207.3M |
| 净利润 | $302.0M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | 97.2% | -54.7% |
| 净利率 | 77.6% | -62.0% |
| 营收同比 | -2.0% | 25.9% |
| 净利润同比 | 1338.1% | 3.5% |
| 每股收益（稀释后） | $1.11 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $389.0M | $207.3M | ||
| Q3 25 | $393.0M | $159.9M | ||
| Q2 25 | $398.0M | $166.5M | ||
| Q1 25 | $397.0M | $139.3M | ||
| Q4 24 | $397.0M | $164.6M | ||
| Q3 24 | $401.0M | $139.5M | ||
| Q2 24 | $404.0M | $147.0M | ||
| Q1 24 | $407.0M | $108.8M |
| Q4 25 | $302.0M | $-128.6M | ||
| Q3 25 | $403.0M | $-180.4M | ||
| Q2 25 | $299.0M | $-115.0M | ||
| Q1 25 | $274.0M | $-151.1M | ||
| Q4 24 | $21.0M | $-133.2M | ||
| Q3 24 | $283.0M | $-133.5M | ||
| Q2 24 | $317.0M | $-131.6M | ||
| Q1 24 | $338.0M | $-170.7M |
| Q4 25 | 97.2% | -54.7% | ||
| Q3 25 | — | -106.9% | ||
| Q2 25 | 95.5% | -64.8% | ||
| Q1 25 | 87.9% | -102.6% | ||
| Q4 24 | 5.3% | -74.3% | ||
| Q3 24 | 90.0% | -94.6% | ||
| Q2 24 | 99.5% | -79.1% | ||
| Q1 24 | — | -151.9% |
| Q4 25 | 77.6% | -62.0% | ||
| Q3 25 | 102.5% | -112.8% | ||
| Q2 25 | 75.1% | -69.0% | ||
| Q1 25 | 69.0% | -108.5% | ||
| Q4 24 | 5.3% | -80.9% | ||
| Q3 24 | 70.6% | -95.7% | ||
| Q2 24 | 78.5% | -89.5% | ||
| Q1 24 | 83.0% | -156.8% |
| Q4 25 | $1.11 | $-1.28 | ||
| Q3 25 | $1.48 | $-1.81 | ||
| Q2 25 | $1.10 | $-1.17 | ||
| Q1 25 | $1.00 | $-1.57 | ||
| Q4 24 | $0.07 | $-1.34 | ||
| Q3 24 | $1.04 | $-1.40 | ||
| Q2 24 | $1.17 | $-1.52 | ||
| Q1 24 | $1.24 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $421.0M |
| 总债务越低越好 | $3.0B | — |
| 股东权益账面价值 | $11.6B | $-80.0M |
| 总资产 | $69.4B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.26× | — |
8季度趋势，按日历期对齐
| Q4 25 | — | $421.0M | ||
| Q3 25 | — | $202.5M | ||
| Q2 25 | — | $176.3M | ||
| Q1 25 | — | $127.1M | ||
| Q4 24 | — | $174.0M | ||
| Q3 24 | — | $150.6M | ||
| Q2 24 | — | $480.7M | ||
| Q1 24 | — | $112.3M |
| Q4 25 | $3.0B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $3.0B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $11.6B | $-80.0M | ||
| Q3 25 | $11.3B | $9.2M | ||
| Q2 25 | $10.7B | $151.3M | ||
| Q1 25 | $10.3B | $144.2M | ||
| Q4 24 | $10.5B | $255.0M | ||
| Q3 24 | $10.8B | $346.8M | ||
| Q2 24 | $9.9B | $432.4M | ||
| Q1 24 | $9.7B | $140.3M |
| Q4 25 | $69.4B | $1.5B | ||
| Q3 25 | $69.8B | $1.2B | ||
| Q2 25 | $68.9B | $1.3B | ||
| Q1 25 | $67.3B | $1.3B | ||
| Q4 24 | $66.5B | $1.5B | ||
| Q3 24 | $67.4B | $1.5B | ||
| Q2 24 | $65.2B | $1.6B | ||
| Q1 24 | $65.1B | $1.3B |
| Q4 25 | 0.26× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $570.0M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $542.0M | $-100.8M |
| 自由现金流率自由现金流/营收 | 139.3% | -48.6% |
| 资本支出强度资本支出/营收 | 7.2% | 0.5% |
| 现金转化率经营现金流/净利润 | 1.89× | — |
| 过去12个月自由现金流最近4个季度 | $2.4B | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $570.0M | $-99.8M | ||
| Q3 25 | $720.0M | $-91.4M | ||
| Q2 25 | $562.0M | $-108.3M | ||
| Q1 25 | $638.0M | $-166.5M | ||
| Q4 24 | $703.0M | $-79.3M | ||
| Q3 24 | $748.0M | $-67.0M | ||
| Q2 24 | $616.0M | $-77.0M | ||
| Q1 24 | $504.0M | $-190.7M |
| Q4 25 | $542.0M | $-100.8M | ||
| Q3 25 | $704.0M | $-92.7M | ||
| Q2 25 | $538.0M | $-110.7M | ||
| Q1 25 | $620.0M | $-167.8M | ||
| Q4 24 | $665.0M | $-79.5M | ||
| Q3 24 | $730.0M | $-68.6M | ||
| Q2 24 | $597.0M | $-79.0M | ||
| Q1 24 | $484.0M | $-193.9M |
| Q4 25 | 139.3% | -48.6% | ||
| Q3 25 | 179.1% | -58.0% | ||
| Q2 25 | 135.2% | -66.5% | ||
| Q1 25 | 156.2% | -120.5% | ||
| Q4 24 | 167.5% | -48.3% | ||
| Q3 24 | 182.0% | -49.2% | ||
| Q2 24 | 147.8% | -53.7% | ||
| Q1 24 | 118.9% | -178.2% |
| Q4 25 | 7.2% | 0.5% | ||
| Q3 25 | 4.1% | 0.8% | ||
| Q2 25 | 6.0% | 1.5% | ||
| Q1 25 | 4.5% | 1.0% | ||
| Q4 24 | 9.6% | 0.1% | ||
| Q3 24 | 4.5% | 1.2% | ||
| Q2 24 | 4.7% | 1.4% | ||
| Q1 24 | 4.9% | 3.0% |
| Q4 25 | 1.89× | — | ||
| Q3 25 | 1.79× | — | ||
| Q2 25 | 1.88× | — | ||
| Q1 25 | 2.33× | — | ||
| Q4 24 | 33.48× | — | ||
| Q3 24 | 2.64× | — | ||
| Q2 24 | 1.94× | — | ||
| Q1 24 | 1.49× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CNA
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
